IMMUNOVANT INC

Insider sell‑to‑cover trades at Immunovant are routine tax‑planning moves, not a warning. Focus on its Phase III autoimmune therapy and FDA milestones for real upside.

ImmuneVant insider sells for tax‑management after lupus study setback – insiders still hold 20%+ stake, suggesting long‑term confidence amid short‑term volatility.